HCV core protein modulates the immune response against the HBV surface antigen in mice

Biochemical and Biophysical Research Communications

Volumn 310, Issue 1, 2003, Pages 59-63

  Aguilar, Julio C ^a   Acosta Rivero, Nelson ^a   Dueñas Carrera, Santiago ^a   Grillo, Juan Morales ^a   Pichardo, Dagmara ^a   Urquiza, Dioslaida ^a   Guillen, Gerardo ^a   Muzio, Verena ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Core antigen; Hepatitis B virus; Hepatitis C virus; Virus like particles

Indexed keywords

CORE PROTEIN; MEMBRANE ANTIGEN; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; EVALUATION; FEMALE; HEPATITIS C VIRUS; HOST; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 0141737542     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.120     Document Type: Article

References (25)

1. Berstad A.K.H., Holst J., Mogster B., Haugen I.L., Haneberg B. A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses, which are not enhanced by cholera toxin. Vaccine. 15:1997;1473-1478.
2. Periwal S.B., Kourie K.R., Ramachandaran N., Blakeney S.J., DeBruin S., Zhu D., Zamb T.J., Smith L., Udem S., Eldridge J.H., Shroff K.E., Reilly P.A. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine. 21:2003;376-385.
3. Zhaori G., Sun M., Ogra P. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 158:1988;160-165.
4. Gilligan C.A., Po L.W. Oral vaccines: desing and delivery. Int. J. Pharm. 75:1991;1-24.
5. Fidel P.L., Lynch M.E., Conaway D.H., Tait L., Sobel J.D. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect. Immun. 63:1995;547-553.
6. Levine M.M. Modern vaccines: enteric infections. Lancet. 335:1990;958-961.
7. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 12:1994;387-400.
8. Dalseg R., Wedege E., Haugen I.L., Holst J., Haneberg B. Group B meningococcal OMV vaccine as a mucosal immunogen. Clin. Immunol. Immunopathol. 76:1995;S93.
9. Lobaina Y., Garcia D., Abreu N., Muzio V., Aguilar J.C. Mucosal immunogenicity of the hepatitis B core antigen. Biochem. Biophys. Res. Commun. 300:2003;745-750.
10. J.C. Aguilar, D. Pichardo, V. Muzio, G. Guillén, G. Veliz, M.J. Leal, E. Pentón, Formulations containing virus-like particles as mucosal adjuvant. CU 98/Dec, PCT/CU/99/00006 (1998).
11. Winther B., Innes D.J. The human adenoid. A morphologic study. Arch. Otolaryngol. Head Neck Surg. 120:1994;144-149.
12. Berstad A.K., Andersen S.R., Dalseg R., Dromtorp S., Holst J., Namork E., Haneberg B. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine. 18:2000;1910-1919.
13. Drucker E., Alcabes P.G., Marx P.A. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet. 358:2001;1989-1992.
14. Oliveira L.H., Silva I.R., Xavier B.L., Cavalcanti S.M. Hepatitis B infection among patients attending a sexually transmitted diseases clinic in Rio de Janeiro, Brazil. Mem. Inst. Oswaldo Cruz. 96:2001;635-640.
15. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:1995;41.
16. Bukh J., Purcell R.H., Miller R.H. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc. Natl. Acad. Sci. USA. 91:1994;8239.
17. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
18. Dueñas-Carrera S., Morales J., Acosta-Rivero N., Lorenzo L.J., García C., Ramos T., Guerra I., Peña M. Variable level expression of hepatitis C virus core protein in a prokatyotic system. Analysis of the humoral response in rabbit. Biotecnología Aplicada. 16:1999;226-231.
19. Lorenzo L.J., Dueñas-Carrera S., Falcon V., Acosta-Rivero N., Gonzalez E., de la Rosa M.C., Menendez I., Morales J. Assembly of truncated HCV core antigen into virus-like particles in Escherichia coli. Biochem. Biophys. Res. Commun. 281:2001;962-965.
20. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:1997;235-270.
21. Milich D.R., Schodel F., Hughes J.L., Jones J.E., Peterson D.L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J. Virol. 71:1997;2192-2201.
22. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 168:2002;4951-4959.
23. Shimoike T., Mimori S., Tani H., Matsuura Y., Miyamura T. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J. Virol. 73:1999;9718-9725.
24. Kunkel M., Lorinczi M., Rijnbrand R., Lemon S., Watowich S. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J. Virol. 75:2001;2119-2129.
25. Botarelli P., Brunetto M.R., Minutello M.A., Calvo P., Unutmaz D., Weiner A.J., Choo Q.L., Shuster J.R., Kuo G., Bonino F.et al. T-lymphocyte response to hepatitis c virus in different clinical courses of infection. Gastroenterology. 104:1993;580-587.